Trials / Completed
CompletedNCT05362734
Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue Trigger
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,396 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- Female
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Ovarian hyperstimulation syndrome (OHSS) is one of the most dangerous complications of assisted reproduction technology (ART), described in approximatively 3 to 10% of stimulation cycles although an underestimation of the real incidence has been suggested. The use in clinical practice of GnRH antagonist has made it possible to perform the trigger with GnRH analogues, with the advantage of considerably reducing the risk of OHSS.
Detailed description
The main concerns about the trigger with analogue are about obstetric outcomes, since it may increase the Abortion Rate (AR) and reduce the Ongoing Pregnancy Rate (OPR) due to luteal phase deficiency, and on the other hand about oocyte quality and competence. While in order to maximize the chance of pregnancy at fresh embryo transfer after GnRHa trigger, several studies have focused on the importance of luteal phase support, other authors suggest that the best strategy is freeze-all: cryopreservation of all the obtained embryos and subsequent single embryo transfers. However, data about oocyte quality, retrieval rate, pregnancy rate and reduced occurrence of complications such as OHSS, especially on the very first embryo transfer, are still scarce.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | obstetric outcomes after fresh versus cryopreserved embryo transfer | measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
- First posted
- 2022-05-05
- Last updated
- 2023-07-07
Source: ClinicalTrials.gov record NCT05362734. Inclusion in this directory is not an endorsement.